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Abstract: Severe periodontitis is ranked as the sixth most prevalent disease affecting humankind,
with an estimated 740 million people affected worldwide. The diagnosis of periodontal diseases
mainly relies upon assessment of conventional clinical parameters. However, these parameters
reflect past, rather than current, clinical status or future disease progression and, likely, outcome of
periodontal treatment. Specific and sensitive biomarkers for periodontal diseases have been examined
widely to address these issues and some biomarkers have been translated as point-of-care (PoC) tests.
The aim of this review was to provide an update on PoC tests for use in the diagnosis and management
of periodontal diseases. Among the PoC tests developed so far, active matrix metalloproteinase-8
has shown promising results in terms of diagnostic and prognostic values. However, further studies
are required to increase the sensitivity and specificity via combining more than one biomarker and
merging these test kits with periodontal risk assessment tools. Furthermore, the validity of these test
kits needs to be investigated by applying the results in further independent studies and the impact
on these test kits’, together with the results of risk factors for periodontal diseases, such as diabetes
and smoking, also needs to be examined.
Keywords: periodontal diseases; diagnostic; prognostic; biomarkers; MMP8; point-of-care test
1. Introduction
Periodontitis is one of the most prevalent chronic inflammatory diseases, characterized clinically
by loss of attachment, pathological deepening of the gingival sulcus, and formation of periodontal
pockets with resorption of supporting alveolar bone [1]. The initiation and progression of these events
are the consequences of an interaction between pathogenic bacteria in the subgingival dental biofilm
around teeth and the host response [2]. The effects of periodontitis are not confined locally to the
periodontium, and the association with various systemic diseases, such as diabetes, atherosclerosis,
cancers, and Alzheimer’s disease, has been suggested [3–6]. In general, the destruction of periodontal
tissues is slow, being characterized by periods of disease activity and remission without obvious
alarming symptoms. If neglected, permanent periodontal destruction may occur. Gingivitis may
progress to periodontitis and thus, the early diagnosis of gingivitis is an effective way for decreasing
the risk of developing periodontitis [7].
Periodontitis is a global public health issue. It affects nearly half of UK adults [8] and is the 6th
most predominant disease worldwide, with an overall prevalence of 11.2% affecting around 743 million
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individuals. The global burden of periodontal disease increased by 57.3% from 1990 to 2010 [9–11].
Previous epidemiological studies have found that the highest prevalence of periodontitis is in elderly
populations (82%), followed by other adults (73%) and adolescents (59%) [10,11]. People in lower
socio-economic groups are disproportionately affected by periodontal disease [9].
Periodontitis is one of the main reasons for tooth loss, which as a consequence can impair
mastication, esthetics, self-confidence, and quality of life, as well as socio-economic impacts and
increasing healthcare costs [12]. The effect on quality of life is increased by greater extent and severity
of periodontal disease [13].
Tissues surrounding dental implants are affected by pathological conditions similar to periodontal
diseases affecting the natural dentition [14]. Peri-implant diseases are broadly classified into two
clinical conditions, namely peri-implant mucositis and peri-implantitis. Peri-implant mucositis is a
reversible inflammatory reaction of the soft tissue around the implant, whereas peri-implantitis is a
progressive inflammation extending to the bone surrounding the fixture resulting in bone resorption
and, ultimately, loss of the implant [15]. It has been estimated that peri-implantitis affects 7% of
dental implants 10 years after placement [16]. Microbiological studies have implicated Gram-negative
anaerobic bacteria in the initiation and progression of both peri-implant disease and periodontitis [17].
Internationally, over burdening of the healthcare system economy due to periodontitis has been
reported. The global cost of lost productivity suffered from severe periodontitis has been estimated to be
54 billion USD/year [12]. In the UK, the total cost was £2.8 billion in 2008 [18]. The cumulative economic
impact of periodontal diseases forms a major component of the 442 billion USD direct and indirect oral
diseases costs worldwide [19]. The treatment of peri-implantitis is also costly and, in advanced cases,
may necessitate complex treatment using bone substitutes and regenerative techniques [20]. Thus,
the treatment of peri-implant disease represents a further potential financial burden to both patients
and health care systems.
2. Diagnosis of Periodontal Diseases
The diagnosis of periodontal diseases may be defined as the act of recognizing disease from
signs and symptoms within the periodontal tissues, indicating a deviation from health. The aim
of periodontal disease diagnosis is to determine the type, severity, and location of periodontal
destruction. This information gives the basis for effective treatment planning and maintenance care [21].
Currently, the diagnosis of periodontal disease depends largely on the presence and extent of gingival
inflammation, which is measured by clinical parameters, including bleeding on probing (BOP) [22],
probing pocket depth (PPD) [23], gingival recession, clinical attachment loss (CAL) [24], tooth mobility,
and the radiographic pattern and extent of alveolar bone loss. Additionally, consideration is given to
age, medical and dental histories, previous treatment, signs and symptoms, including pain, ulceration,
and microbial deposits [25]. In clinical practice, the instrument used for periodontal diagnosis is mainly
a blunt-ended periodontal probe with millimeter graduations to measure PPD, recession, and CAL,
together with BOP. Furthermore, radiographs are used to determine the presence and pattern of
alveolar bone loss, which can be detected in people affected by periodontitis.
In 2017, a world consensus from the European Federation of Periodontology (EFP) and the
American Academy of Periodontology (AAP) proposed a new classification of periodontal diseases [26].
This sought to add clarity to earlier classifications, taking into account the disease severity/extent
and progression by applying a staging and grading system, including both past disease destruction
and the intricacy of required therapies [27]. Staging presents the severity of disease, while grading
gives additional information about biological characteristics of the disease. For example, a history
based assessment of the rate of disease progression, an evaluation of the risk for further progression,
the expected response to treatment, and an assessment of the risk that the disease or its therapy may
have on oral health are taken into account [27]. However, the new classification system does not
focus comprehensively on the definition and criteria for diagnosing peri-implant diseases, which is
based mainly on BOP and radiographic evidence of bone loss [26]. These clinical parameters alone are
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insufficiently reliable to identify active peri-implant disease, future crestal bone loss, or future implant
failure [28]. Developing methods for accurate diagnosis and predicting the prognosis of peri-implant
disease is of paramount importance for the appropriate clinical management and long-term survival of
dental implants.
3. Limitations of Traditional Methods for Diagnosis
The traditional methods for diagnosing periodontal diseases are based mainly on the clinical
periodontal parameters mentioned above. Supplementary information, such as medical and familial
histories, distinctive features, such as bone loss at early age and the amount of dental plaque, is also
considered [29]. Whilst this information is helpful, there are a number of limitations. For example,
the current diagnostic method is time-consuming and can only indicate past tissue destruction. It does
not provide information about the current disease activity nor its future progression and the likely
response to treatment.
Furthermore, these clinical methods are subjective, as several factors can affect the outcome of
periodontal probing, including the design of the probe tip, the pressure applied by the examiner,
the angulation of the probe, inter- or intra-examiner variability, the tolerance of the patient, and whether
the examination is performed on a healthy or periodontitis patient [30,31]. A further issue associated
with conventional periodontal examination, especially full-mouth probing, is the potential for
measurement error due to subjectivity. These drawbacks are further amplified when large-scale
epidemiological surveys are conducted that require intra- and inter-examiner calibration. Although the
manual periodontal probe is the cheapest and easiest examination instrument, it is not ideal when
accuracy and reproducibility are required [30,31]. Additionally, BOP used as an indication of
local inflammation, is not a reliable marker for detecting the disease activity, future tissue damage.
For example, only approximately 30% of sites that bleed on probing on each of successive examinations
are likely to undergo further disease progression [32]. In addition, conventional radiographs only
display alveolar bone loss when 30–50% of bone mineral is lost in a particular area [33]. Furthermore,
repeat measurement of the above clinical parameters, with the potential for further errors, is performed
to monitor clinical outcomes in the management of patients with periodontal and peri-implant
diseases [34].
The assessment of dental implants using probing is not without risk, as the force used may
jeopardize the vulnerable peri-implant tissues [35,36]. Consequently, radiographic examination of bone
loss is also used to assess the status of dental implants. A previous study that utilized an experimental
animal model aiming to compare probing forces around natural teeth and dental implants showed that
the latter were associated with deeper probe penetration [37]. Furthermore, probing around dental
implants cannot be performed until 6 months after loading or placement of the implant, at which time
osseointegration is complete [35]. Another limitation is related to the objective of probing around the
implant, as it is primarily used to detect the presence of bleeding and/or suppuration [36,37].
Several developments have been introduced to improve the defects of conventional diagnosis,
such as pressure-sensitive probes, automated digital probes, and subtraction radiography, that offer
more reliable and precise methods for diagnosing periodontal diseases. However, these techniques are
mostly used for academic research purposes rather than daily routine clinical practice [38]. Therefore,
new diagnostic tests need to be developed which can detect active disease, as well as future disease
progression and predict the likely response to periodontal treatment. This information may assist in
targeting resources for treatment.
4. Need for Alternative Methods with Diagnostic and Prognostic Potential, Such as Use of Biomarkers
Since the 1920s, there have been many changes in the classification of periodontal diseases
in an attempt to reach the most accurate diagnosis in order to facilitate treatment planning [26].
The latest classification system aimed to address issues associated with the previous classification
system and to provide a standard universal platform that can be easily used by periodontists and
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general practitioners [39]. Nevertheless, debates and controversies about the current classification
system continue, mostly centered around the staging of periodontitis, which may result in confusion
about the definitive diagnosis. The intention was to include biomarkers during development of the
new classification scheme [39]. However, this was omitted due to the lack of sufficient evidence and
global standardized methods for the assessment of biomarkers. The new classification scheme is
designed to enable the incorporation of changes in light of future developments [39]. In support for
this notion, a recent study aimed to incorporate a point-of-care (PoC) mouth rinse test into the new
classification system. The authors have suggested the usefulness of this test as a rapid and effective
adjunct diagnostic tool in determining grading and staging of periodontitis [40].
The limitations associated with traditional diagnostic methods, has led to research into laboratory
and chairside tests. Diagnostic accuracy, ease of use, and low cost are important attributes for such
tests if these are to become widely used. These criteria have been met in a commercial product, the PoC
mouth rinse immunotest, which can measure the level of active matrix metalloproteinase 8 (aMMP8)
within 5 min and assist in diagnosis and predicting the prognosis of periodontitis [41,42]. Despite the
revolutionary concept of using a chair-side PoC test and the advances that have been achieved, the use
of these novel assays remains in the research field, and their application in routine dental practice is
limited [43].
A search of the literature reveals the number of studies examining biomarkers in oral fluids
as diagnostic tools for periodontal disease has markedly increased in the last decade (Figure 1).
MMP8 is shown separately here due to its importance. It is anticipated that increased understanding
of biomarkers in periodontal health and disease will lead to the further development of chair-side
technologies enabling dental practitioners to diagnose periodontal diseases and to predict the prognosis
and responsiveness to periodontal therapy. Furthermore, biomarkers may be useful in screening as an
adjunct in epidemiological studies.
 
 
Figure 1. Number of studies examined biomarkers for periodontal diseases from 1974 to 2020 (PubMed).
5. Sources of Biomarkers of Periodontal Disease in the Oral Cavity
Saliva, gingival crevicular fluid (GCF), peri-implant sulcular fluid (PISF), and mouth rinse remnant
constitute reliable sources of biomarkers in the oral cavity that are readily available. These fluids
may be collected non-invasively, with a high potential to reflect periodontal health and disease status
through examining the biomarkers within them [44]. However, certain limitations affect the quality
and quantity of each fluid collected. Several methods have been described for the collection of GCF,
such as absorption onto paper strips, microcapillary pipetting, and sulcular washing methods [45,46].
Despite the fact that GCF provides high levels of different biomarkers, the volume of this fluid is
drastically altered in response to health or disease [47]. This fluctuation greatly influences collection
time by microcapillary pipetting, which ranges from 10 min for diseased sites up to 40 min in healthy
sites [48,49]. In contrast, absorption methods require relatively much less time, for example, 30–60 s for
collecting GCF/PISF. However, variation in the manufactured quality of the paper points or paper strips
used could affect their absorptive efficiency, and difficulties may also occur in retrieving the target
molecules from the paper-strips/points [46,50]. Furthermore, using a washing technique is technically
demanding and is usually associated with gingival irritation [50]. In general, with all methods for
GCF/PISF collection, there is the possibility of contaminating the sample with blood or saliva that
could affect the test outcome and would require repeating the sampling procedure [46].
Saliva is rich in a wide array of biomarkers that can be easily collected and stored in larger
amounts than GCF without any potential trauma to the periodontal tissues [51]. Errors associated with
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interpretation of salivary samples are mostly related to variations in the volume and composition of
saliva. These may be due to differences in pathological and physiological states between individuals,
as well as within the same person at different times. These make the standardization and quantification
of biomarkers difficult when collecting cross-sectional or longitudinal samples [52,53]. In addition,
the presence of other elements in saliva, such as mucin and cell debris, can make it hard to
manipulate [54].
The issues related to whole salivary samples can be overcome by collecting mouth rinse samples
that provide as accurate results as saliva regarding the discrimination between periodontal health
and disease [55]. A further potential sampling variable is that the operator can determine the volume
collected, which accordingly may vary between patients. The reliability of the latter fluid as a source of
biomarkers (aMMP8, in particular) has been documented in many studies, and it could represent the
best option for investigating various biomarkers [41].
6. Potential Biomarkers of Periodontal Diseases
A biomarker was defined by the National Institutes of Health Biomarkers Definitions Working
Group as “a characteristic that is objectively measured and evaluated as an indicator of normal biological
processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention” [56]. In the
last decade, attempts have been made to move periodontal examination from classical methods into
using biomarkers that can quantify and qualify relevant clinical information objectively [34]. However,
the integrity of certain biomarkers is limited by the availability of specific criteria (Figure 2).
 
 
Ά
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Figure 2. Criteria for the ideal biomarker.
Ideally, the biomarker must be valid, safe to use, easily measured, affordable, and able to be
collected non-invasively [56]. In addition, it should be highly sensitive to correctly identify those with
disease (true-positive) and specific to precisely identify those without disease (true-negative) [57].
These criteria increase the accuracy of the biomarker as a predictive and diagnostic tool and for efficiently
reflecting the patients’ responses to treatment. Furthermore, consistency of results across different
ethnic groups, ages, and genders is an important characteristic of an ideal biomarker. This section
describes the most promising biomarkers of periodontal and peri-implant diseases.
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6.1. IL1β
Interleukin (IL)-1β is a potent inflammatory mediator which is critical for the host response
to infection or injury. Most of the tissue damage that occurs during chronic or acute diseases or
injuries is attributed to this cytokine that is mainly secreted by monocytes and macrophages [58].
Indeed, IL1β is one of the inflammatory mediators highly involved in the pathogenesis of periodontal
diseases. Susceptibility of individuals to develop periodontitis was found to be associated with
IL1β gene (3953/4C>T) polymorphisms [59]. Further, subjects with IL1β gene polymorphisms showed
increased levels of “orange” and “red” complex periodontal pathogens, which are considered as
the main cause of periodontal diseases [60]. It is important to acknowledge that polymorphisms
of other IL1 genes, such as IL1RN, has been shown to reduce the susceptibility to aggressive and
chronic periodontitis via decreasing load of Porphyromonas gingivalis (P. gingivalis), Tannerella forsythia
(T. forsythia), and Prevotella intermedia [61]. Similarly, to the natural dentition, IL1β + 3954C/T genetic
polymorphisms were found to be associated with an increased risk of peri-implantitis [62].
The level of IL1β has been found to be significantly and positively associated with increasing PPD
and BOP [63]. Analyses of GCF samples from 100 individuals over 12 months have indicated that IL1β
is a potential biomarker that can predict periodontal disease progression [64]. A case-control study that
monitored salivary IL1β in periodontitis patients before and after phase I treatment showed a significant
difference in the level of IL1β between healthy controls and a periodontitis group at baseline [65].
Miller et al. demonstrated that IL1β salivary level significantly increased during periodontal disease
compared to controls [66]. Further studies highlighted the ability of IL1β to identify subjects at risk of
developing progressive periodontitis and an association of increased IL1β concentration in saliva with
increasing rate of bone loss and CAL [66,67].
Utilization of this cytokine as a biochemical marker to distinguish between disease and health
status of peri-implant tissue has been demonstrated by several studies. Assessment of IL1β level
in PISF over 12 months suggested its usefulness as adjunct to clinical parameters and radiographs
in detecting early inflammation around dental implants [68]. Additionally, levels of IL1β were
significantly higher in whole salivary samples [69] and PISF samples collected from patients with
peri-implantitis, compared with healthy controls [70].
Evidence from available data favors using IL1β as a diagnostic biomarker, predictor of
periodontal/peri-implant disease progression, and for monitoring treatment outcomes. However,
the use of this biomarker is still limited to the research field, and it has not yet been translated as a
chair side test for clinical practice.
6.2. IL6
IL-6 is one of the key acute-phase reactants, and is released by a variety of immune and non-immune
cells at the inflammatory site, although macrophages and monocytes are considered as the main source
for this cytokine [71]. Involvement of IL-6 in the pathogenesis of periodontal disease is well-recognized.
A previous meta-analysis aimed to compare levels of different cytokines in healthy and periodontitis
subjects, with response to the treatment indicating increased IL-6 in GCF in the periodontitis group [72].
The susceptibility to periodontitis seems to be increased with IL-6 gene 174/G>C polymorphism [73].
Investigation of the IL-6 salivary level in patients with mild, moderate, and severe periodontitis
in comparison to healthy controls, showed that IL-6 level proportionally increased with the severity of
periodontitis, which suggests the potential diagnostic ability of IL-6 [74]. Another cross-sectional study
concluded that IL-6 significantly discriminates between periodontal health and disease in pregnant
women [75]. The salivary concentration of IL-6 significantly increased in obese individuals with high
cumulative risk score for periodontitis [76]. Furthermore, the level of IL-6 in GCF samples of type
2 diabetes mellitus patients with periodontitis was significantly higher than in systemically-healthy
people with or without periodontitis [77]. Comparison of IL-6 level in PISF samples collected from
healthy implants and those with peri-implantitis, showed that diseased sites exhibited significantly
higher IL-6 levels [70]. Furthermore, levels of IL-6 in whole saliva samples were significantly higher in
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patients with peri-implantitis than healthy controls [69]. Indeed, IL-6 possesses potential characteristics
to be used as a valid, sensitive, and specific biomarker for periodontal/peri-implant disease. However,
further studies are required in order to develop a chair-side-PoC test that can be utilized effectively by
dentists in clinical settings.
6.3. MMP8
Matrix metalloproteinases (MMP) family members are enzymes mainly responsible for degrading
all extracellular matrix and basement membrane proteins during physiologic remodeling [78].
During disease, MMP8 is one of the major collagenolytic enzymes highly involved in the destruction of
periodontal/peri-implant tissue and progression of periodontitis/peri-implantitis [79]. The level of these
biomarkers and MMP8, in particular, were markedly upregulated in proportion to the severity of disease,
which potentially makes it possible to measure and accurately reflect the past, current, and anticipated
clinical condition [80,81]. Levels of MMP8 considerably increase in oral fluids in association with
progressively advancing periodontal/peri-implant diseases [79–81]. Recently, the effectiveness of
PoC/chair-side testing using saliva, GCF, PISF, and mouth rinse has been comprehensively reviewed [82].
MMP8 is present in oral fluids in detectable amounts that can provide clinically significant
and meaningful readings. The main source of this collagenase is degranulated polymorphonuclear
leukocytes (PMN) cells, which release up to 20% of their content as MMP8 [83]. On average, each 106
PMN secretes about 60 ng of MMP8, mostly in latent form, which once activated degrades type I and II
collagens [79,83,84]. Although PMNs are the major contributors of MMP8 (Figure 3), this collagenase
can be derived from other non-PMN lineage sources, including fibroblasts, epithelial cells, endothelial
cells, macrophages, and smooth muscle cells [83,85,86]. The salivary MMP8 is derived from PMNs
leaking from gingival sulcus to the oral cavity rather than being secreted by major salivary glands [87].
This notion is supported by the high resemblance of salivary MMP8 to GCF/PISF counterparts in its
molecular weight (70,000 daltons), with a similar tendency to be activated by gold thioglucose, and lyse
the same collagen types [88]. Moreover, the amount of MMP8 was significantly reduced in edentulous
subjects when compared to dentate individuals [89].
 
 
ぽ ぼ
Figure 3. Sources of matrix metalloproteinase (MMP) 8 in oral fluids. Polymorphonuclear leukocytes
(PMN) cells represent the main source for MMP8 following their degranulation. MMP8 then released
into gingival crevicular fluid (GCF), peri-implant sulcular fluid (PISF), saliva, and mouthrinse samples.
MMP8 is also released to a lesser extent from other immune and non-immune cells together with
other cytokines, including interleukin (IL) 8, IL1β, tumor necrosis factor (TNF)-α, receptor activator of
nuclear factor kappa-B ligand (RANKL), osteoprotegerin (OPG), and prostaglandin E2 (PGE2).
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The presence of pathogenic bacteria, mainly red complex group, in the dental biofilm stimulates
production of a range of cytokines, such as tumor necrosis factor-α (TNF-α), IL1β, and MMP8,
through Toll-like receptor (TLR) signaling downstream [90]. Among periodontal pathogens,
Treponema denticola (T. denticola) and T. forsythia were found to have the potential to induce the
inflammatory cascade associated with increased expression of MMP8 [91]. In addition, T. denticola and
P. gingivalis proteases are able to directly activate human pro-collagenases, i.e., by converting latent
MMP8 into its activated form [92].
In health, MMP8 in oral fluids is mainly in its latent form, while the expression of the activated form
increases in response to periodontal/peri-implant diseases [86,93]. The activity, severity, progression,
and response to the treatment of these diseases were found to be significantly and positively associated
with the level of aMMP8 [79,94]. Currently, MMP8-based assays are available as chair-side kits that
are sensitive, time-saving, specific and accurate in discriminating periodontal health and disease.
Indeed, introduction of an MMP8-based point of care test that utilizes saliva as a platform for
periodontal disease testing is a “game changer” that not only provides information about the current
situation but also identifies susceptible individuals and prognosis of treatment [79,80,95]. A study
conducted on Finnish adolescents showed that an active MMP8 PoC test can effectively detect
initial periodontitis associated with single nucleotide polymorphisms of VDR and MMP3 genes [96].
Measurement of aMMP8 by lateral-flow chair-side/PoC immunoassay showed that it was highly
sensitive to periodontitis, with at least two sites exhibiting PPD ≥5mm [97]. Association of aMMP8
level with clinical parameters [95,97,98] and radiographic findings has been demonstrated by several
studies [99,100]. Although a chair-side/PoC aMMP-8 test could not discriminate between smokers and
non-smokers with progressive periodontitis [101], it was demonstrated that this assay could effectively
predict the prognosis of smokers, in that elevated baseline-MMP8 levels indicated a poor response to
treatment [102] and sites that were non-responsive to treatment continued expressing high levels of
aMMP8 [101].
Pathologically involved peri-implant sites showed a similar pattern of elevated MMP8 level in
PISF to that observed in periodontitis sites [103–105], with a similar cellular source being mainly
derived from inflammatory cells, particularly PMNs (Figure 3) [105]. Increased severity of bone loss
and osteolytic activity during peri-implantitis was found to be associated with the aMMP-8 level in
PISF [105], which was further confirmed by another study [106]. Results from a 10 years retrospective
analysis, showed a positive correlation between upregulated MMP8 expression in GCF and PISF,
and the degree of inflammation [89]. Similar to the natural dentition, the response of tissues supporting
dental implants to treatment can be predicted by measuring aMMP-8 levels in oral fluids [85].
Cut-off points of aMMP8 have been determined for a healthy state (<6.46 ng/mL),
gingivitis/peri-mucositis (6.64–20 ng/mL), periodontitis/peri-implantitis that respond favorably to
the treatment (20–60 ng/mL), and progressive periodontitis that does not respond to the treatment
(>60 ng/mL) [107–109] (Figure 4). Table 1 summarizes several studies that have investigated the use
of MMP8 by different assays for periodontal/peri-implant diseases and which indicate the efficiency
of this biomarker in different aspects related to diagnosis and prediction of treatment outcomes for
periodontal/peri-implant diseases.
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Figure 4. Cut off point of aMMP8 to differentiate periodontal/peri-implant health and disease. The cut
off value of aMMP8 that differentiates from health (green dotted line) and gingivitis/peri-mucositis
(blue continuous line) is equal to 6.46 ng/mL. While aMMP8 levels ≥20 ng/mL represent the cut
off value distinguishing gingivitis/peri-mucositis from periodontitis/peri-implantitis. The latter two
conditions could respond favorably to periodontal therapy which is reflected by downregulation of
aMMP8 expression in oral fluids (black continuous line) or the destruction of periodontal tissues further
progress if neglected (orange continuous line). aMMP8 levels exceeding 60 ng/mL potentially predict
poor prognosis of periodontitis/peri-implantitis to periodontal treatment.
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Table 1. Summary of studies that investigated MMP8 using different assay techniques for periodontal/peri-implant health and disease in oral fluids.
Authors Aim(s) Study Groups
Oral Fluids
Examined *
Biomarkers, Assays † Clinical Criteria ¶ Results
Ma et al., 2000
[105]
Investigate the correlation
between GI, MMP8, and MMP13
level in PISF and amount of
peri-implant bone loss
13 patients having
implants with
different levels of
bone resorption
PISF
MMP8 by time-resolved
immunofluorometric
assay and MMP13 by
quantitative immunoblot
Peri-implant vertical bone
loss was divided into: <1
mm, 1–3 mm, and >3mm
Gingival inflammation
recorded on scale from
0–3
Both biomarkers
potentially reflect osteolytic
process but not GI
Yamazaki-Kubota
et al., 2010 [110]
Investigate the level of MMP2,
MMP8, and subgingival bacteria
in children with Down’s
syndrome
Children with DS
(n = 15)
Healthy controls
(n = 14)
GCF MMP2 and MMP8(ELISA) OHI, PPD, and BOP
Both collagenolytic
enzymes were significantly
higher in GCF of children
with DS than controls even
with low oral hygiene index
score and absence of BOP.
Rai et al., 2010
[111]
Investigate the level of MMP8
and MMP9 in healthy
periodontium and periodontitis
Periodontitis
patients (n = 10)
Healthy controls
(n = 10)
GCF Both MMPs measured byELISA
At least 7 teeth with PPD
>6 mm
Having at least 12
posterior teeth
Significantly higher level of
MMP8 and MMP9 in
periodontitis vs healthy
controls
Leppilahti et al.,
2011 [112]
Assessing the ability of PoC
MMP8- mouth rinse, measured
by three assays, TIMP1, and
elastase activity to distinguish
subjects with different
periodontal conditions.
Comparing assaying methods for
MMP8
Randomly
selected patients
with periodontitis
(n = 214)
Mouth rinse samples
MMP8 assayed by IFMA,
DentoELISA and
commercial ELISA.
TIMP1 and elastase
measured by ELISA
BOP, PPD ≥4 mm, and
PIBI
MMP-8/TIMP-1
combination showed
higher diagnostic accuracy
DentoELISA showed
higher sensitivity and
specificity in detecting
MMP8
Kraft-Neumärker
et al., 2012 [113]
Full-mouth analysis to
investigate the correlation
between clinical parameters and
level of MMP8
Females with
periodontitis (n =
9)
GCF MMP8 assayed by ELISA GI, PI, BOP, and PPD(>30% of sites affected)
Increased PPD was
associated with increased
level of MMP8
Ebersole et al.,
2013 [114]
Investigating the level of selected
biomarkers in periodontal health
and periodontal disease
Healthy (n = 30)
Periodontitis (n =
50)
Saliva
IL1β, IL6, TNFα, and
IFNα assayed by human
Luminex® multiplex
assays
MMP8, PGE2, and
albumin assayed by
ELISA
Healthy:
BOP <10% of sites, PPD
≤6 mm in <2% of sites,
CAL >2 mm in <1% of
sites
Periodontitis:
PPD ≥5 mm, CAL ≥3 mm,
BOP ≥2 in at least 5 sites
Salivary MMP8, IL1β, and
IL6 showed the highest
diagnostic potential
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Table 1. Cont.
Authors Aim(s) Study Groups
Oral Fluids
Examined *
Biomarkers, Assays † Clinical Criteria ¶ Results
Leppilahti et al.,
2014 [115]
Assess the accuracy of different
biomarkers in diagnosing
periodontitis
Comparing two methods for
assaying MMP8
Healthy (n = 20
sites)
Gingivitis (n = 19
sites)
Periodontitis (n =
19 sites)
GCF
MPO, TIMP1 MMP13,
and MMP14. Assayed by
ELISA
MMP8 Assayed by ELISA
and IFMA
Healthy:
PPD <3 mm, no CAL, no
inflammation
Gingivitis:
BOP with no loss of
attachment
Periodontitis:
PPD ≥5 mm, CAL ≥3
mm, >50% bone loss in
radiograph
MPO and MMP8 can highly
discriminate periodontitis.
IFMA is more accurate than
ELISA for assaying MMP8
Liu and Hwang,
2016 [116]
Assessment of the effect of
smoking cessation on
periodontal tissue over 12
months
Male smokers
joined smoking
cessation clinic (n
= 122)
GCF, Saliva
MMP8, MMP9, and IL1β
measured by ELISA,
nicotine and cotinine
assayed by
chromatography-tandem
mass spectrometry
PI, GI
Patients exhibiting sites
>5.5 mm were excluded
The level of MMP8 did not
change significantly within
the monitoring period
between smokers,
quit-smokers, oscillators
and nonsmokers
Ramseier et al.,
2016 [89]
Assessment of biomarkers in
PISF 10 years after implant
placement
Implants (n = 504),
adjacent teeth (n =
493)
GCF, PISF
MMP8, IL1β, MMP3,
MMP1, and
MMP1/TIMP1 measured
by ELISA
PI, mGI, BOP, PPD, and
CAL
Increased level of MMP8
was detected in 90% of sites
with progressive
inflammation around
tooth/implant
Gul et al., 2016
[117]
To assess combined biomarkers
compared with single biomarker
for predicting
the outcome of treatment
Periodontitis
patients (n = 30) GCF
Active MMP8, elastase,
cathepsin G, trypsin like
enzyme and sialidase
measured by colorimetric
assay
Full mouth PI, BOP, PPD
and CAL
Combined active enzyme
profiling could
provide significant
prediction of outcome of
treatment.
Kumar et al., 2017
[118]
Evaluate the response of
peri-implant connective tissue to
titanium and zirconia abutments
Candidates for
implant
placement (n = 12)
PISF MMP8 assayed by ELISA
GI, PI, and PPD measured
by thermoplastic
periodontal sensor probe
Titanium abutment
induced higher expression
of MMP8 at early stages
than zirconia
Gul et al., 2017
[119]
Assess the ability of a novel
combination of biomarkers
to predict treatment outcome of
patients with chronic
periodontitis
Periodontitis
patients (n = 77) GCF and plaque
Active MMP8, elastase
and sialidase measured
by colorimetric assay, Pg,
Tf and Td level
determined by qPCR.
Full mouth PI, BOP, PPD
and CAL
The “fingerprint” of GCF
enzymes and bacteria offers
a way to predict the
outcome of
non-surgical periodontal
treatment on a site-specific
basis.
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Table 1. Cont.
Authors Aim(s) Study Groups
Oral Fluids
Examined *
Biomarkers, Assays † Clinical Criteria ¶ Results
Mauramo et al.,
2018 [98]
Assessment of association
between MMP8 level in oral
fluids and periodontitis
Periodontitis
patients (n = 258) GCF, Saliva MMP8 assayed by IFMA DMFT, BOP, PPD, CAL
MMP8 in saliva and GCF
was significantly associated
with severity of
periodontitis and PPD
Borges et al., 2019
[120]
Investigate attachment loss at
sites with progressive
periodontal disease following
SRP
Periodontitis
stage II grade B (n
= 18)
Healthy controls
(n = 9)
Saliva, GCF
IL-10, MMP8, VEGF,
RANKL, OPG and
TGF-β1 by Multiplex
Cytokine Profiling Assay
MMP8 level measured by
ELISA
PPD, BOP, and relative
CAL
Attachment loss continued
in some sites even after SRP.
Action of MMP8 seems to
be modulated by IL-10
Hong et al., 2020
[107]
Comparing efficiency and
accuracy of different biomarkers
in diagnosing gingivitis
Healthy (n = 15)
Gingivitis (n = 85) Saliva and GCF
MMP8, MMP9, cystatin
C, MPO, PAF, cathepsin B,
lactoferrin, and ICTP
ELISA
Gingivitis defined by
BOP ≥10%
MMP8 and MPO were
significantly and positively
correlated with BOP.
MMP8 was the most
effective in diagnosis of
gingivitis
Karteva and
Manchorova-Veleva,
2020 [121]
Assessing the accuracy of active
(a)MMP8 in diagnosis of
asymptomatic apical
periodontitis (AAP)
AAP (n = 31)
Control (n = 31) GCF aMMP8 by ELISA
CBCT used to confirm the
presence of the lesion
Statistically significant
increase in aMMP8 level
collected from teeth with
AAP compared to healthy
controls
Liu et al., 2020
[122]
Application of the combined use
of baseline salivary biomarkers
and clinical parameters in
predicting the outcome of scaling
and root planning
Advance
periodontitis (n =
40)
Saliva
MMP8 and IL1β by
ELISA, Pg, Aa, Pi and Tf
by PCR.
PPD, BOP, and CAL
The combination of
baseline salivary
biomarkers and clinical
parameters better predicted
SRP outcomes
than each alone
* GCF, gingival crevicular fluid; PISF, peri-implant sulcular fluid; † MMP, matrix metalloproteinase; MPO, myeloperoxidase; PAF, platelet-activating factor; ICTP, pyridinoline cross-linked
carboxyterminal telopeptide of type I collagen; IFMA, immunofluorometric assay; IFNα, interferon-α; PGE2, prostaglandin E2; Pg, Porphyromonas gingivalis; Aa, Aggregatibacter
actinomycetemcomitans; Pi, Prevotella intermedia; Tf, annerella forsythia; Td, Treponema denticola; TIMP, tissue inhibitors of metalloproteinase; IL, interleukin; TNF, tumor necrosis factor; VEGF,
vascular endothelial growth factor; RANKL, receptor activator of nuclear factor kappa-B ligand; OPG, osteoprotegerin; TGF-B1, transforming growth factor beta 1; ¶ PPD, probing pocket depth; CAL,
clinical attachment loss; BOP, bleeding on probing; PI, plaque index; GI, gingival index; CBCT, cone beam computed tomography; DMFS, decayed-missed-filled surface index; PBI, papilla
bleeding index; OHI, oral hygiene index; mGI, gingival index modified for oral implants; DMFT, decayed, missing and filled teeth; SRP, scaling and root planning.
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6.4. Single vs Combination of Biomarkers
Although some biomarkers can be considered as hallmarks of the current status and progression
of periodontal disease [99], certain systemic and local factors may alter the expression of a specific
or group of biomarkers, hence compromising their accuracy in diagnosing periodontal diseases.
For instance, a recent study has indicated a reduction in the diagnostic accuracy of aMMP-8 PoC
oral rinse immunotest in patients affected by Crohn’s disease as compared to systemically-healthy
controls [123]. In addition, despite the excellence of MMP8 in differentiating periodontal disease
from health state, its level in saliva could be altered due to caries activity [124], increased body mass
index (BMI) [125] and smoking [126], which may compromise the diagnostic accuracy, especially in
diagnosing early stages of periodontitis. The sensitivity of PoC aMMP8 mouth rinse testing was shown
to be lower for single-site pockets and BOP than multiple sites exhibiting bleeding and PPD [97].
Medication may also affect the level of MMP8 expressed, such as host modulation with low doses
of certain drugs as an adjunct to conventional treatment(s) of periodontitis/peri-implantitis, mainly
aiming to modify destructive aspects of the host inflammatory response [127]. Doxycycline (20 mg) is
a well-recognized host response modulator with marked MMP8-inhibitory action [128]. Low dose
administration of doxycycline does not cause bacterial resistance, cross-resistance with other antibiotics,
or compromise normal flora even after a prolonged intake period, yet, it is effective in counteracting
MMP8 [79,128]. Therefore, data from patients using doxycycline should be interpreted with caution,
taking into account its inhibitory effect against MMP8.
It has been questioned whether diagnostic accuracy is better when using a single biomarker or
biomarker profile. Several studies have been conducted to weigh the advantages of combining different
biomarkers over an individual biomarker for predicting and detecting periodontal/peri-implant
diseases. The diagnostic accuracy for periodontal disease and its severity was significantly enhanced
by measuring multiple salivary biomarkers, including MMP8, MMP9, and osteoprotegerin, together
with qPCR, for P. gingivalis and T. denticola in dental biofilms [129]. Receiver operating characteristic
curves analysis has determined the possible thresholds of different biomarkers combined with
levels of P. gingivalis and T. forsythia that possibly distinguish healthy from periodontally-involved
sites [119]. A previous study showed that the sensitivity and specificity of aMMP8 alone was
greatly diminished in differentiating healthy controls from periodontitis subjects with smoking [126].
However, aMMP8 with other biomarkers, such as tissue inhibitor of matrix metalloproteinases (TIMP)
1 and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), improved the
diagnostic accuracy even in smokers [126]. A cohort study that included seven biomarkers showed
that IL-1β, IL-6 and MMP-8 combination was the most sensitive and specific for discriminating health
from periodontitis [114]. Consistently, synergetic diagnostic accuracy of aMMP8/TIMP1 was also
suggested in other studies [112,130]. Gursoy et al. (2011) calculated the cumulative risk score for
three salivary biomarkers, IL1β, MMP8, and P. gingivalis, for periodontitis patients [131]. The results
indicated that these biomarkers can diagnose advanced periodontitis more accurately in combination
than on an individual basis [131]. Recently, the cumulative risk score for periodontitis has been
strongly associated with microbial biomarker species and salivary humoral immunity [132]. Treatment
predictivity of single vs multiple biomarkers was evaluated by previous studies, which concluded
that combinations of MMP8, elastase, and sialidase could be more accurate than a single enzyme as
prognostic tools [117,119].
7. Detection Methods for Biomarkers in Periodontal Diseases
Biomarkers can be used as a basis for the early detection of periodontal disease, future progression,
and response to treatment, which can consequently serve for better treatment planning and prognosis.
In parallel to the use of different sources (Saliva, GCF, PISF, mouth rinse, and serum) for biomarkers’
measurements, different assays have been used for detection. In general, Immunoassays, such as
Immunoblot, immunofluorometric assay (IFMA), ELISA, DentoELISA, and Dento-Analyzer, have
been used to determine the levels of biomarkers [100,115]. The presence of high affinity and specific
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antibodies is the basic communality between these assays [133,134]. Immunoblot is a sensitive method
for the detection of biomarkers, especially when discrimination between active and latent forms is
required, although determination of the levels of biomarkers is very difficult. Moreover, owing to high
cost, the need for specialized equipment, trained staff, and a time-consuming procedure, immunoblot
is not adaptable for clinical use [135]. Compared to all assays used, ELISA has been shown to be
more sensitive, quantitative and flexible for conducting testing of more than one biomarker in the
same sample [136,137]. However, it cannot be used in the dental clinic, as running the assay requires
specialized equipment and trained staff. Furthermore, ELISA cannot differentiate the active and
latent forms of biomarkers, such as MMP8. This is problematic as the initiation and progression of
periodontal disease, and responsiveness to the treatment are more associated with the active form of
MMP8 rather than the total enzyme [84,138]. Antibodies that can specifically recognize the active form
of MMP8 are of paramount importance.
Substrate degradation assays which measure the active form of an enzyme through degradation
of a specific substrate by the enzyme do not require antibodies. The reporter substrate could
be a radiolabeled substrate, fluorogenic substrate and change in absorbance in colorimetric assay.
Nevertheless, substrate degradation assays also require time and specialized equipment and are,
therefore, not adaptable for use in the clinic [139]. On the other hand, detection of periodontal pathogens
as biomarkers has been investigated using various test kits as discussed in Section 8. Quantitative PCR
is the most sensitive and specific technique used to detect the levels of bacterial pathogens. Translating
qPCR into PoC test kits would be of great value in the diagnosis and prognosis of periodontal and
peri-implant diseases. However, these are not available currently [140].
In this context, a new PoC technology, “Lab-on-a-Chip” (LOC), has been developed which
integrates several laboratory assays in a single miniature device, including sampling procedure,
preparation of the sample, detection and measurements of multiple biomarkers, and analysis [141].
The drawbacks of using a combination of biomarkers includes the complexity of interpreting the
results and the manufacturing process, together with the considerable cost implications, which
contradict the WHO’s ASSURED criteria (affordable, sensitive, specific, user-friendly, rapid and robust,
equipment-free and deliverable to end-users) for PoC devices [142]. However, the evidence from the
aforementioned studies supports the potential for improvement in diagnostic accuracy by including
more than one biomarker in a cost-effective PoC tests.
Recently, two new PoC chairside test kits have been developed, PerioSafe® and ImplantSafe®,
to detect the level of active MMP8 above 20ng/mL using immune-assay [82]. The kits, similar to
pregnancy tests, provide two lines of results indicating higher risk of periodontitis. The advantages
of these tests are that they are inexpensive, do not require specialized equipment or trained staff,
and provide a quick result within 5 min having high sensitivity and specificity similar to ELISA,
which makes them more adaptable for use in clinic. The disadvantage of these PoC test kits is that
only a single biomarker is integrated, which is difficult to reflect the complex nature of periodontal
diseases [94,108,143,144]. Table 2 summarizes some studies that used PoC aMMP8-chair-side tests to
examine periodontal/peri-implant health and disease in oral fluids, as well as that produced promising
results in clinical practice.
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Table 2. Summary of studies that used point-of-care (PoC) aMMP8-chair-side tests to examine oral fluids for periodontal/peri-implant health and disease.
Author, Year Aim(s) Study Groups Oral Fluid Examined PoC/Chairside Test Clinical Criteria ¶ Results
Mäntylä et al.,
2006 [101]
Evaluate the efficacy of MMP8-
specific chair-side dip-stick test
in longitudinal monitoring of
periodontal status of smoker and
non-smoker periodontitis
patients
Periodontitis patients
(n = 16) GCF
MMP8 assayed by
chair-side dipstick
test
Have at least 20 teeth, BOP,
PPD ≥4 mm at 5 or more
sites, PI, and CAL
Persistent elevation of
MMP8 in GCF may
indicate sites at risk and
poor response to
conventional nonsurgical
periodontal treatment
Sorsa et al., 2010
[81]
Comparing four methods to
detect MMP8 in GCF
Periodontally healthy
(n = 2), gingivitis (n = 2),
moderate-severe
periodontitis (n = 6)
GCF
IFMA, MMP-8
specific chair-side
dip-stick test,
Dento-Analyzer, and
Amersham ELISA kit
PPD, AL
IFMA and Dento-Analyzer
yielded comparable results,
followed by chair-side
dip-stick test, while
Amersham ELISA results
were not in line with other
assays
Nwhator et al.,
2014 [97]
Investigate the clinical correlates
of aMMP8-immunotest with
BOP, oral hygiene, and PPD
Periodontitis and healthy
(n = 86), Final analysis
included 76 patients
Mouth rinse samples
aMMP8 measured by
Lateral flow mouth
rinse test
(PerioMarker®)
BOP, debris index and
calculus index scores, and
BPE, PPD was charted when
BPE score> 3
aMMP8 showed high
sensitivity for at least two
sites with BOP and two
sites with periodontal
pockets
Izadi Borujeni
et al., 2015 [95]
To evaluate the sensitivity and
specificity of aMMP8 PoC
immunotest in detecting
periodontitis
Untreated generalized
periodontitis (n=30
equally distributed
between moderate and
severe cases)
Healthy controls (n = 30)
Mouth rinse samples
aMMP8 measured by
Lateral flow mouth
rinse test
(PerioMarker®)
Moderate periodontitis: PPD
≥3.5mm, CAL =3–4 mm at
>30% of sites or ≥5 mm at
<30% of sites
Severe periodontitis: PPD
≥3.5 mm, CAL ≥5 mm at
>30% of sites
Healthy: PPD ≤3 mm, CAL
≤2 mm at <30% of sites
aMMP8 positively
correlated with generalized
periodontitis with
diagnostic sensitivity = 87%
and specificity = 60%
Heikkinen et al.,
2016 [41]
Investigate the ability of PoC
aMMP8-mouthrinse to identify
adolescents with oral
inflammatory burden
Adolescent subjects
(n = 47) Mouth rinse samples
aMMP8 measured by
Lateral flow mouth
rinse test
Full-mouth clinical
parameters, including BOP,
PI, PPD ≥4mm, and caries
sites
aMMP-8 chairside test
effectively differentiated
adolescents with early
initial signs of periodontitis.
However, caries was less
efficiently detected
Ritzer et al.,
2017 [106]
Determine the efficiency of
sensory chewing gums as 24/7
detector to differentiate between
patients with peri-implant
disease and healthy subjects
Peri-implantitis or
mucositis group and
healthy volunteers
PISF, Unstimulated
saliva
aMMP-8 levels were
assayed by
DentoELISA,
Dento-Analyzer, and
peptide sensor (PCL
ID #1c)
N/A
Level of MMP8 was
significantly higher in
patients with peri-implant
diseases as compared to
healthy controls
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Table 2. Cont.
Author, Year Aim(s) Study Groups Oral Fluid Examined PoC/Chairside Test Clinical Criteria ¶ Results
Heikkinen et al.,
2017 [96]
Determination of genetic
background for initial
periodontitis and caries by PoC
aMMP8 immunotest
Adolescent subjects
(n = 47) Oral fluid samples
aMMP8 measured by
Lateral flow mouth
rinse test
(PerioSafe®)
BOP ≥20% of sites, PPD, PI,
and caries status
Genetic polymorphisms of
MMP3 and VDR
significantly associated
with aMMP8 level
Räisänen et al.,
2018 [109]
Investigate the effectiveness of
aMMP8 PoC immunotest in
determining cost-effective
treatment(s)
Adolescents (n = 47)
Adults (n = 70) Mouth rinse samples
aMMP8 measured by
Lateral flow mouth
rinse test
Treatment need defined by
CPITN scores
Results from aMMP8 PoC
immunotest were
consistent with CPITN
codes for treatment needs
Grigoriadis
et al., 2019 [145]
Using aMMP8 PoC immunotest
for screening prediabetes and
diabetes state in periodontal
patients
Healthy (n = 21)
Periodontitis: Stage I/II,
grade A-C (n = 48)
Mouth rinse samples
Capillary blood
aMMP8 assayed by
Lateral flow mouth
rinse
immunoassay test
and digital reader
ORALyzer®
Blood sugar by
HbA1c test
PPD and BOP were measured
HbA1c and aMMP8 PoC
test can provide dentists
with opportunity to
diagnose prediabetic and
diabetic patients
Räisänen et al.,
2019 [146]
Comparing the effectiveness of
aMMP8 PoC mouthwash vs BOP
in detection pre-/subclinical
periodontitis in adolescents
47 adolescents (30 male
and 17 female) Mouth rinse samples
aMMP8
Lateral flow
immunoassay test
(PerioSafe®)
BOP (20% of sites), PPD≥
4mm, PI, bitewing
radiographs for premolars
and molars
aMMP8 was twice higher
in terms of sensitivity and
more accurate than BOP in
detecting early stages than
BOP
Schmalz et al.,
2019 [147]
Investigate the association of
aMMP8 with severity of
periodontitis, periodontal
bacteria, and blood parameters
Periodontitis patients
(n = 188):
Mild (n = 50)
Moderate (n = 111)
Severe (n = 27)
Mouth rinse samples,
blood
aMMP8 measured by
Lateral flow
immunoassay test
(Periomarker®)
Based on PPD and CAL,
severity of periodontitis was
divided into mild, moderate,
and severe
aMMP8 was positively
associated with severity of
periodontitis and anaerobes
highly involved in
periodontal destruction
Rautava et al.,
2020 [123]
Compare the accuracy of aMMP8
PoC immunotest in subjects with
and without Crohn’s disease
(CD)
Controls (n = 47)
CD (n = 41) Mouth rinse samples
Lateral flow mouth
rinse test
(PerioSafe®)
Oral mucosal examination
for CD-related lesions
Caries prevalence by DMFS
Gingivitis defined by BOP
≥15% of sites with no CAL or
PPD
Periodontitis defined by:
PPD ≥4 mm, CAL ≥2 mm
with or without BOP
Discrimination accuracy of
aMMP8 PoC immunotest
reduced and diagnosis of
periodontitis was
compromised with CD
patients
Sorsa et al., 2020
[40]
Assessing the usefulness of
aMMP8 point of care (PoC)
mouthwash in the interpretation
of the “Staging” and “Grading”
of the new classification system
for periodontal disease
Healthy (n = 31)
Periodontitis (n = 119) Mouth rinse samples
Lateral flow mouth
rinse test
(PerioSafe®)
and ORALyzer®
Healthy:
BOP <10% of sites
Periodontitis:
Defined according to the new
classification system 2018
aMMP8 PoC mouthwash
can be integrated for
staging and grading of
periodontitis
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Sorsa et al., 2020
[148]
Investigate the effectiveness of
aMMP8 PoC mouthwash in
diagnosing peri-implantitis
Healthy subjects (n = 20)
Peri-implantitis (n = 20) Mouth rinse samples
aMMP8
Lateral flow
immunoassay test
(ImplantSafe®)
Peri-implantitis, diagnosed
clinically and
radiographically
aMMP8 PoC test correctly
diagnosed all healthy and
Peri-implantitis cases
Lähteenmäki
et al., 2020 [149]
Assessing the accuracy aMMP-8
PISF POC test (ImplantSafe) as
compared to other biomarkers of
peri-implantitis.
Evaluating the value of aMMP-8
lateral-flow PoC technologies in
non-invasively monitoring
periodontal treatment outcomes
Patients with
peri-implantitis (n = 26)
Healthy control (n = 26)
Periodontitis patients
(n = 15)
PISF, mouth rinse
samples
aMMP8
Lateral flow
immunoassay test
(ImplantSafe®),
(PerioSafe®)
Peri-implantitis, diagnosed
by presence of PPD ≥4mm,
BOP, radiographic bone loss
≥2 mm, PI, FI, mobility index
Self-reported oral health
(SROH)-questionnaires
aMMP8 PoC test
discriminated health from
peri-implantitis with higher
accuracy than BOP,
PMN-elastase, MMP9,
TIMP1, and
myeloperoxidase
SROH can be used as
adjunctive diagnostic
method but not as
alternative for oral fluid
biomarkers
MMP, matrix metalloproteinase; IFMA, immunofluorometric assay; ¶ PPD, probing pocket depth; CAL, clinical attachment loss; BOP, bleeding on probing; PI, plaque index; BPE, basic
periodontal examination; PISF, peri-implant sulcular fluid; CPITN, community periodontal index for treatment need; DMFS, decayed-missed-filled surface index; FI, furcation involvement;
TIMP, tissue inhibitor of metalloproteinase.
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8. Periodontal Point-of-Care Test Kits
PoC technology aims to evaluate the levels of biomarkers that have shown to be associated with
the disease status. These tests have already been used in general medicine for blood coagulation,
immunological, and cardiovascular biomarkers. Moreover, some of these tests, such as pregnancy tests
and for blood glucose levels, are available for home use [150]. There is potential for developing further
PoC tests in medicine, and the WHO has introduced the ASSURED criteria for the characteristics of
PoC devices. This stipulates that such devices should be “affordable, sensitive, specific, user friendly,
rapid, and robust, with no complex equipment and deliverable to end-users” [142].
The development of a PoC test for periodontal diseases that meets the above criteria would be of
great value and make life easier for researchers, clinicians, and patients. Since the 1990s, many test
kits that have been introduced as prototypes or for commercial use have relied upon chemical,
immunological, and microbiological techniques for the evaluation of biomarkers. The idea was to
develop a test kit with enhanced diagnostic and prognostic capabilities [151]. This section will review
the applicability and usefulness of these kits through the studies that have examined them. In general,
the chairside kits can be classified into three groups.
8.1. Microbiological Test Kits
Microbiological test kits have been used to detect periodontopathogenic bacteria that play a
role in periodontal diseases, such as A. actinomycetemcomitans, P. gingivalis, P. intermedia, T. forsythia,
and T. denticola. Evaluation of these bacteria can be used to determine the most common forms of the
disease, such as gingivitis and periodontitis (formerly called chronic and aggressive periodontitis).
These tests were used to assess the reduction or eradication of periodontal pathogens during periodontal
therapy [140]; however, they could not fully satisfy clinical needs. For example, Omnigen diagnostics
takes hours to days to perform, Evalusite has very low sensitivity, and PerioScan can only determine
the severity of the disease (Table 3).
8.2. Biochemical Test Kits
These kits have mainly been used to determine levels of biomarkers in oral fluids. Molecules,
such as enzymes (bacterial and host enzymes), mediators of inflammation, and extracellular matrix
components that represent the alteration of periodontal tissues have been investigated [38]. Amongst the
molecules, enzymes (MMP8 in particular) have been mainly examined and translated as chair side tests.
Generally, these tests are not widely used in the clinic because of complex procedure, low sensitivity
and specificity [38], whereas, the more recently developed PoC test kits, namely PerioSafe® and
ImplantSafe®, can provide results within 5–7 min, with sensitivity and specificity of 76.5% and 96.7%,
respectively [41,94] (Table 3).
8.3. Genetic Test Kits
Genetic polymorphisms of IL-1α and IL-1β are likely to be related to an individual’s genetic
susceptibility to periodontitis. Although these genes do not cause or initiate the disease, they might
enhance earlier development and severity of the periodontitis [140]. GenoTypePST® and MyperioID
tests are used to determine the genetic susceptibility to periodontitis (Table 3).
The biomarkers that have been examined in relation to PoC test kits (Table 3) have been shown
to identify the severity of periodontal diseases [54,140,152]. However, apart from PerioSafe® and
ImplantSafe®, none of these tests have demonstrated the prognostic capabilities of importance to both
clinician and patient. Additionally, these tests have been shown not to comply with ASSURED criteria
for diagnostic devices [153]. Thus, some of these tests, indeed the majority, are no longer available or
rarely used in clinics.
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Table 3. Summary of diagnostic biomarker test kits for periodontal diseases [140,152,153].
Assay Commercial Kit Sample Target?
Microbial test kit
PerioScan Subgingival plaque Utilizes the BANA test forbacterial trypsin-like proteases
IAI Pado test Subgingival plaque Aa, Pg, Tf, and Td
Evalusite test Subgingival plaque, GCF Aa, Pi, and Pg
TOPAS Subgingival plaque, GCF
Toxins derived from anaerobic
metabolism and measures GCF
protein level
Omnigene® diagnosctics Saliva Pg, Pi, Aa, Fn, Tf, Td, Ec, and Cr
Biochemical test
Prognostik GCF Serine proteinases and elastase
Pocketwatch GCF
Detects aspartate
aminotransferase through
colorimetric detection
Periogard GCF Detects the presence of aspartateaminotransferase
Periocheck GCF Detects presence of neutralproteinases (collagenase)
Progno-Stik GCF Elastase
PerioMarker® GCF Activated MMP8
Dip Stick GCF MMP8
Perio 2000 GCF, Subgingival plaque Sulfides in periodontal pockets
PerioSafe® GCF, Mouth rinse Activated MMP8
ImplantSafe® GCF, PISF Activated MMP8
ORALyzer® GCF, Mouth rinse, Saliva Activated MMP8
Integrated microfluidic
platform for oral diagnostics Saliva MMP8
Oral Fluid NanoSensor test Saliva IL-1 and IL-8
Electronic taste chip Saliva C reactive protien
Genetic test kits
GenoType®PST® Saliva
Interleukin (IL-1α and IL-1β)
genes polymorphism
MyperioID Saliva Genetic variation/polymorphismwithin the IL-1 gene
GCF: gingival crevicular fluid, PISF: peri-implant sulcular fluid, Aa: Aggregatibacter actinomycetemcomitans,
Pg: Porphyromonas gingivalis, Tf: Tannerella forsythia, Td: Treponema denticola, Pi: Prevotella intermedia, Fn:
Fusobacterium nucleatum, Ec: Eikenella corrodens, Cr: Campylobacter rectus.
9. Clinical Implications and Challenges
In modern dental clinics, the diagnosis of periodontal diseases entirely depends on assessment
of clinical parameters of BOP, PPD, CAL, and bone loss. However, these clinical parameters have
limitations, including the detection of past rather than current disease activity, lack prognostic value to
predict further disease progression, and response to periodontal therapy [153]. Additionally, full mouth
clinical assessment is always challenging for clinicians in the dental clinic and for researchers, as it
takes time, and, for that reason, basic periodontal examination coding and partial mouth recoding
have been developed for clinical and researcher examination, respectively [154,155].
Amongst the PoC test kits, PerioSafe® and ImplantSafe® have shown to be the most reliable
and applicable [40,94,108,156]. Their reliability as diagnostic kits are demonstrated by their ability to
differentiate gingivitis and periodontitis from healthy periodontium by the cut off value of 6.46 ng/mL.
Furthermore, they can differentiate gingivitis and periodontitis by the cut-off point of 20 ng/mL
(Figure 4). This is of great value, as these results can be used as a screening tool for patients in the
clinic and in research settings where time is limited. In dental clinics, this helps the clinician to exclude
the patients that do not require periodontal examination because an MMP8 level <6.46 ng/mL shows
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that they have a healthy periodontium, or it might encourage the clinician to provide a thorough
treatment plan for patients with periodontitis through integrating these test results into the 2017
classification system when the MMP8 level is in the active range from 20–60 ng/mL [40,94,108,156].
In periodontal studies and epidemiological surveys, the prevalence of the most serious form of the
disease (periodontitis) could be determined more quickly and accurately by conducting the PerioSafe®
test instead of a very time-consuming full mouth periodontal examination of a large number of
participants, using a partial mouth protocol or examining representative teeth (CPITN indexed teeth),
which have been shown to produce inaccurate results [157]. Even more important is the prognostic
value of the PerioSafe® test kit in enabling the clinician to identify patients that are at high risk
of further periodontal tissue destruction (MMP8 ranges from 20–60 ng/mL) or not responding to
standard periodontal treatment (scaling and root surface debridement) when the active MMP8 level
>60 ng/mL [79,94,100,108,146].
General dental practitioners could integrate this test’s results in their referral to a specialist
periodontist, which can save time in the referral process and thereby protecting the patients’ periodontal
health. For the periodontist, the clinical implications include helping to prioritize treatment and in
organizing follow-up appointments. In addition, these tests have the potential to reduce over or
under treatment by enabling customized tailored treatment strategies to be developed. For instance,
a test result suggesting a patient might not respond to standard periodontal treatment (MMP8
>60 ng/mL), may help the periodontist to decide how best to manage residual sites after initial
treatment. This may include the prescription of an adjunctive treatment (local or systemic antibiotic) to
accompany further non-surgical treatment or the provision of surgical treatment (open root surface
debridement) [42,85,94,143].
Despite the above significant clinical implications, studies that have investigated biomarkers of
periodontal diseases have some limitations. For example, the developed test kits are not yet widely
accepted by clinicians in routine daily practice [140], which might be related to the fact that clinicians
want a diagnostic test that will make a difference in their daily clinical routine, and that is not the case
with most of the test kits developed so far, whereas, among the PoC test kits listed above (Table 3),
PerioSafe® and ImplantSafe® are compliant with ASSURED criteria and have shown promising results.
However, these test kits have shown to be inaccurate in patients with mixed dentition (younger than
15 years old), systemic diseases (Crohn’s diseases) [123], active orthodontic treatment, and mouth
ulcers [82]. Finally, variations in sampling technique, assays used, statistical analysis, and data
reporting, as well as periodontal diseases case definition, make comparisons between the studies
very challenging.
10. Conclusions and Future Direction
This review summarized the limitations of traditional clinical parameters, potent periodontal
disease biomarkers, and developed PoC test kits used in the diagnosis of periodontal and peri-implant
diseases. Biomarker profiles offer the opportunity to obtain a quick overview on present periodontal
disease status, future disease progression, and, likely, response to periodontal therapy. The PerioSafe®
and ImplantSafe® test kits can be at least a helpful adjunct tool in enhancing the diagnosis and
prognosis of periodontal diseases. Future development of PoC test kits should take into account the
ASSURED criteria introduced by WHO. Further studies are necessary to increase the diagnostic and
prognostic value through combining more than a single biomarker and integrating these test kits into
periodontal risk assessment. Furthermore, studies need to be conducted in patients with potential
confounders of periodontal disease (such as diabetes mellitus and smoking) and, most importantly,
to validate the results with other studies.
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